Technical Analysis for FGEN - FibroGen, Inc

Grade Last Price % Change Price Change
grade D 38.83 -1.97% -0.78
FGEN closed down 1.97 percent on Wednesday, October 23, 2019, on 80 percent of normal volume.

Earnings due: Nov 7

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Flat
See historical FGEN trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Multiple of Ten Bearish Other 0.00%
Outside Day Range Expansion 0.00%
Multiple of Ten Bearish Other -1.97%
Overbought Stochastic Strength -1.97%
Multiple of Ten Bearish Other -1.04%
Weak + Overbought Other -1.04%
Inside Day Range Contraction -1.04%
Overbought Stochastic Strength -1.04%
Stochastic Sell Signal Bearish 0.08%

Older signals for FGEN ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
FibroGen, Inc. operates as a research-based biopharmaceutical company in the United States. The company focuses on the discovery, development, and commercialization of therapeutic agents to treat serious unmet medical needs. The company develops roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019, a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. It also focuses on use of the proprietary type III recombinant human collagens in its biosynthetic corneal implant product candidate, FG-5200 for the treatment of corneal blindness. The company was incorporated in 1993 and is headquartered in San Francisco, California.
Biotechnology Biopharmaceutical Life Sciences Chronic Kidney Disease Pancreatic Cancer Anemia Idiopathic Pulmonary Fibrosis Hypoxia Inducible Factors Liver Fibrosis Research Based Biopharmaceutical
Is FGEN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 61.23
52 Week Low 33.51
Average Volume 545,354
200-Day Moving Average 46.4624
50-Day Moving Average 40.5511
20-Day Moving Average 37.7543
10-Day Moving Average 38.812
Average True Range 1.5517
ADX 19.83
+DI 17.1799
-DI 21.8811
Chandelier Exit (Long, 3 ATRs ) 36.5649
Chandelier Exit (Short, 3 ATRs ) 39.2851
Upper Bollinger Band 40.6086
Lower Bollinger Band 34.9
Percent B (%b) 0.69
BandWidth 15.120397
MACD Line -0.2378
MACD Signal Line -0.6752
MACD Histogram 0.4374
Fundamentals Value
Market Cap 2.76 Billion
Num Shares 71.2 Million
EPS -1.92
Price-to-Earnings (P/E) Ratio -20.22
Price-to-Sales 32.73
Price-to-Book 16.72
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 41.16
Resistance 3 (R3) 41.36 40.79 40.77
Resistance 2 (R2) 40.79 40.20 40.69 40.64
Resistance 1 (R1) 39.81 39.83 39.53 39.61 40.51
Pivot Point 39.24 39.24 39.10 39.14 39.24
Support 1 (S1) 38.26 38.65 37.98 38.06 37.15
Support 2 (S2) 37.69 38.28 37.59 37.02
Support 3 (S3) 36.71 37.69 36.89
Support 4 (S4) 36.51